ReviewCurrent heart failure reports2025
Sex and Gender Aspects in New-Onset Heart Failure Prognosis: A Review of Recent Advances.
Review in Current heart failure reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review examines sex-based differences in prognosis and management of new-onset heart failure (HF), focusing on biological, clinical, and sociocultural determinants. RECENT
findingsRecent cohort studies and registries show that women with new-onset HF are older, more often present with HFpEF, and have lower early mortality but higher rehospitalization and worse quality of life. Men frequently present with HFrEF and ischemic etiology, experiencing higher short-term mortality. Emerging biomarkers, including galectin-3 and GDF-15, display sex-specific prognostic value. Persistent underrepresentation of women in clinical trials and disparities in access to guideline-directed therapy remain critical gaps. Sex and gender substantially influence new-onset HF presentation and outcomes. Tailored diagnostic thresholds, sex-informed therapeutic strategies, and equitable research designs are essential to improve care. Future studies should integrate intersectional perspectives and precision medicine approaches to address disparities and optimize prognosis for all patients.
Indexed as
Identifiers
41413736What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.